Hepatic Impairment Study of Encorafenib in Combination With Binimetinib in BRAF Melanoma

Summary

Encorafenib in combination with binimetinib have been approved in USA, Europe, Australia, Japan and Switzerland for the treatment of adult patients with unresectable or metastatic melanoma with BRAF V600 mutation. The main objective of this study is to find a safe and effective dose of encorafenib in combination with binimetinib for patients who have BRAF-mutant metastatic or unresectable melanoma with hepatic dysfunction (i.e. moderate or severe impairment).

Timeline

Start

2021-01-21

Primary completion

2023-05

Completion

2023-05

Outcome

Outcome not reported

Stopped (Enrollment): “no recruitment”

Drugs

Indications